Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Lutz

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2012
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)T Ruers, C Punt, F Van Coevorden, et al.
ESMO Open|February 18, 2022
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspectiveT Koessler, M Alsina, D Arnold, et al.
Zeitschrift Fur Gastroenterologie|March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]M P Ebert, C Auernhammer, K Caca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986C-H Köhne, E van Cutsem, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
Deutsche Medizinische Wochenschrift (1946)|August 24, 2007
[Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies]G Adler, T Seufferlein, S C Bischoff, et al.
Zeitschrift Fur Gastroenterologie|July 4, 2007
[S3-Guidelines "Exocrine pancreatic cancer" 2007]G Adler, T Seufferlein, S C Bischoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2012
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)T Ruers, C Punt, F Van Coevorden, et al.
ESMO Open|February 18, 2022
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspectiveT Koessler, M Alsina, D Arnold, et al.
Zeitschrift Fur Gastroenterologie|March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]M P Ebert, C Auernhammer, K Caca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986C-H Köhne, E van Cutsem, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
Deutsche Medizinische Wochenschrift (1946)|August 24, 2007
[Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies]G Adler, T Seufferlein, S C Bischoff, et al.
Zeitschrift Fur Gastroenterologie|July 4, 2007
[S3-Guidelines "Exocrine pancreatic cancer" 2007]G Adler, T Seufferlein, S C Bischoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Pageof 6